366 related articles for article (PubMed ID: 18230058)
1. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Sonpavde G; Hutson TE; Sternberg CN
Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib: therapeutic developments.
Limvorasak S; Posadas EM
Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib for the treatment of renal cell carcinoma and other malignancies.
Sonpavde G; Hutson TE; Sternberg CN
Drugs Today (Barc); 2009 Sep; 45(9):651-61. PubMed ID: 19956806
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib in renal cell carcinoma.
Ward JE; Stadler WM
Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
Bukowski RM
Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
9. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
Bourdeanu L; Twardowski P; Pal SK
Clin J Oncol Nurs; 2011 Oct; 15(5):513-7. PubMed ID: 21951737
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib: Clinical development of a potent anti-angiogenic drug.
Schutz FA; Choueiri TK; Sternberg CN
Crit Rev Oncol Hematol; 2011 Mar; 77(3):163-71. PubMed ID: 20456972
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
LaPlant KD; Louzon PD
Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
Kasper B; Hohenberger P
Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
Prescrire Int; 2011 Mar; 20(114):64-6. PubMed ID: 21648224
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.
Melichar B; Studentová H; Zezulová M
J BUON; 2011; 16(2):203-9. PubMed ID: 21766486
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib in renal cell carcinoma.
Sternberg CN
Clin Adv Hematol Oncol; 2010 Apr; 8(4):232-3. PubMed ID: 20505644
[No Abstract] [Full Text] [Related]
17. New treatment approaches in renal cell carcinoma.
Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Keisner SV; Shah SR
Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
[TBL] [Abstract][Full Text] [Related]
19. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
20. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Nieto M; Borregaard J; Ersbøll J; ten Bosch GJ; van Zwieten-Boot B; Abadie E; Schellens JH; Pignatti F
Clin Cancer Res; 2011 Nov; 17(21):6608-14. PubMed ID: 21976546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
